A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients with Glioblastoma Multiforme

Study identifier:1839IL/0088

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients with Glioblastoma Multiforme

Medical condition

Glioblastoma

Phase

Phase 2

Healthy volunteers

Study drug

Gefitinib

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2003

Primary Completion Date: -

Study Completion Date: 01 Mar 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

CSR-D7913L00088.pdf
Download
CSR-D7913L00088.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Sweden Medical Director

+46 8 553 229 89

Investigators

Principal Investigator

AstraZeneca Medical Science Director

AstraZeneca